Adult Stem Cel Diferentiation and Trafficking And Their Implications in Disease

  • Ying Zhuge
  • Zhao-Jun Liu
  • Omaida C. Velazquez
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 695)


Stem cells are unspecialized precursor cells that mainly reside in the bone marrow and have important roles in the establishment of embryonic tissue. They also have critical functions during adulthood, where they replenish short-lived mature effector cells and regeneration of injured tissue. They have three main characteristics: self-renewal, differentiation and homeostatic control. In order to maintain a pool of stem cells that support the production of blood cells, stromal elements and connective tissue, stem cells must be able to constantly replenish their own number. They must also possess the ability to differentiate and give rise to a heterogeneous group of functional cells. Finally, stem cells must possess the ability to modulate and balance differentiation and self-renewal according to environmental stimuli and whole-organ needs to prevent the production of excessive number of effector cells.1 In addition to formation of these cells, regulated movement of stem cells is critical for organogenesis, homeostasis and repair in adulthood. Stem cells require specific inputs from particular environments in order to perform their various functions. Some similar trafficking mechanisms are shared by leukocytes, adult and fetal stem cells, as well as cancer stem cells.1,2 Achieving proper trafficking of stem cells will allow increased efficiency of targeted cell therapy and drug delivery.2 In addition, understanding similarities and differences in homing and migration of malignant cancer stem cells will also clarify molecular events of tumor progression and metastasis.2 This chapter focuses on the differentiation, trafficking and homing of the major types of adult bone marrow stem cells: hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs) and the term“stem cell” will refer to “adult stem cells” unless otherwise specified.


Stem Cell Progenitor Cell Mesenchymal Stem Cell Hematopoietic Stem Cell Cancer Stem Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007; 58:267–84.PubMedGoogle Scholar
  2. 2.
    Laird DJ, von Andrian UH, Wagers AJ. Stem cell trafficking in tissue development, growth and disease. Cell 2008; 132(4):612–30.PubMedGoogle Scholar
  3. 3.
    Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 2008; 132(4):631–44.PubMedGoogle Scholar
  4. 4.
    Orkin SH. Diversification of haematopoietic stem cells to specific lineages. Nat Rev Genet 2000; 1(1):57–64.PubMedGoogle Scholar
  5. 5.
    Kim SI, Bresnick EH. Transcriptional control of erythropoiesis: emerging mechanisms and principles. Oncogene 2007; 26(47):6777–94.PubMedGoogle Scholar
  6. 6.
    Mikkola HK, Klintman J, Yang H et al. Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. Nature 2003; 421(6922):547–51.PubMedGoogle Scholar
  7. 7.
    Ichikawa M, Asai T, Saito T et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 2004; 10(3):299–304.PubMedGoogle Scholar
  8. 8.
    Kulessa H, Frampton J, Graf T. GATA-1 reprograms avian myelomonocytic cell lines into eosinophils, thromboblasts and erythroblasts. Genes Dev 1995; 9(10):1250–62.PubMedGoogle Scholar
  9. 9.
    Nerlov C, Graf T. PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev 1998; 12(15):2403–12.PubMedGoogle Scholar
  10. 10.
    Nutt SL, Heavey B, Rolink AG et al. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 1999; 401(6753):556–62.PubMedGoogle Scholar
  11. 11.
    McDevitt MA, Shivdasani RA, Fujiwara Y et al. A “knockdown” mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc Natl Acad Sci USA 1997; 94(13):6781–5.PubMedGoogle Scholar
  12. 12.
    Orkin SH. Priming the hematopoietic pump. Immunity 2003; 19(5):633–4.PubMedGoogle Scholar
  13. 13.
    Chen H, Ray-Gallet D, Zhang P et al. PU.1 (Spi-1) autoregulates its expression in myeloid cells. Oncogene 1995; 11(8):1549–60.PubMedGoogle Scholar
  14. 14.
    Tsai SF, Strauss E, Orkin SH. Functional analysis and in vivo footprinting implicate the erythroid transcription factor GATA-1 as a positive regulator of its own promoter. Genes Dev 1991; 5(6):919–31.PubMedGoogle Scholar
  15. 15.
    Iwasaki H, Akashi K. Myeloid lineage commitment from the hematopoietic stem cell. Immunity 2007; 26(6):726–40.PubMedGoogle Scholar
  16. 16.
    Laiosa CV, Stadtfeld M, Xie H et al. Reprogramming of committed T-cell progenitors to macrophages and dendritic cells by C/EBP alpha and PU.1 transcription factors. Immunity 2006; 25(5):731–44.PubMedGoogle Scholar
  17. 17.
    Xie H, Ye M, Feng R et al. Stepwise reprogramming of B cells into macrophages. Cell 2004; 117(5):663–76.PubMedGoogle Scholar
  18. 18.
    Busslinger M, Nutt SL, Rolink AG. Lineage commitment in lymphopoiesis. Curr Opin Immunol 2000; 12(2):151–8.PubMedGoogle Scholar
  19. 19.
    Zhang P, Zhang X, Iwama A et al. PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding. Blood 2000; 96(8):2641–8.PubMedGoogle Scholar
  20. 20.
    Nerlov C, Querfurth E, Kulessa H et al. GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1-dependent transcription. Blood 2000; 95(8):2543–51.PubMedGoogle Scholar
  21. 21.
    Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T-cells. Cell 1997; 89(4):587–96.PubMedGoogle Scholar
  22. 22.
    Szabo SJ, Kim ST, Costa GL et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100(6):655–69.PubMedGoogle Scholar
  23. 23.
    Wechsler J, Greene M, McDevitt MA et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32(1):148–52.PubMedGoogle Scholar
  24. 24.
    Mueller BU, Pabst T, Osato M et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 2002;100(3):998–1007.PubMedGoogle Scholar
  25. 25.
    Pabst T, Mueller BU, Zhang P et al. Dominant-negative mutations of CEBPA, encoding CCAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001; 27(3):263–70.PubMedGoogle Scholar
  26. 26.
    Mullighan CG, Goorha S, Radtke I et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446(7137):758–64.PubMedGoogle Scholar
  27. 27.
    Liu ZJ, Zhuge Y, Velazquez OC. Trafficking and differentiation of mesenchymal stem cells. J Cell Biochem 2009;106(6):984–91.PubMedGoogle Scholar
  28. 28.
    Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8(4):315–7.PubMedGoogle Scholar
  29. 29.
    Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts and assays. Cell Stem Cell 2008; 2(4):313–9.PubMedGoogle Scholar
  30. 30.
    Chen FH, Rousche KT, Tuan RS. Technology Insight: adult stem cells in cartilage regeneration and tissue engineering. Nat Clin Pract Rheumatol 2006; 2(7):373–82.PubMedGoogle Scholar
  31. 31.
    Mimeault M, Batra SK. Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer. Gut 2008; 57(10):1456–68.PubMedGoogle Scholar
  32. 32.
    Baksh D, Tuan RS. Canonical and noncanonical Wnts differentially affect the development potential of primary isolate of human bone marrow mesenchymal stem cells. J Cell Physiol 2007; 212(3):817–26.PubMedGoogle Scholar
  33. 33.
    Barry F, Boynton RE, Liu B et al. Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation-dependent gene expression of matrix components. Exp Cell Res 2001; 268(2):189–200.PubMedGoogle Scholar
  34. 34.
    Ito T, Sawada R, Fujiwara Y et al. FGF-2 increases osteogenic and chondrogenic differentiation potentials of human mesenchymal stem cells by inactivation of TGF-beta signaling. Cytotechnology 2008; 56(1):1–7.PubMedGoogle Scholar
  35. 35.
    Kratchmarova I, Blagoev B, Haack-Sorensen M et al. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science 2005; 308(5727):1472–7.PubMedGoogle Scholar
  36. 36.
    Matsuda C, Takagi M, Hattori T et al. Differentiation of Human Bone Marrow Mesenchymal Stem Cells to Chondrocytes for Construction of Three-dimensional Cartilage Tissue. Cytotechnology 2005; 47(1–3):11–7.PubMedGoogle Scholar
  37. 37.
    Nedeau AE, Bauer RJ, Gallagher K et al. A CXCL5-and bFGF-dependent effect of PDGF-B-activated fibroblasts in promoting trafficking and differentiation of bone marrow-derived mesenchymal stem cells. Exp Cell Res 2008; 314(11–12):2176–86.PubMedGoogle Scholar
  38. 38.
    Tsuchiya H, Kitoh H, Sugiura F et al. Chondrogenesis enhanced by overexpression of sox9 gene in mouse bone marrow-derived mesenchymal stem cells. Biochem Biophys Res Commun 2003; 301(2):338–43.PubMedGoogle Scholar
  39. 39.
    Hristov M, Weber C. Progenitor cell trafficking in the vascular wall. J Thromb Haemost 2009; 7 Suppl 1:31–4.PubMedGoogle Scholar
  40. 40.
    Zhang D, Fan GC, Zhou X et al. Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. J Mol Cell Cardiol 2008; 44(2):281–92.PubMedGoogle Scholar
  41. 41.
    Haider H, Jiang S, Idris NM et al. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ Res 2008; 103(11):1300–8.PubMedGoogle Scholar
  42. 42.
    Chavakis E, Hain A, Vinci M et al. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 2007; 100(2):204–12.PubMedGoogle Scholar
  43. 43.
    Palumbo R, Bianchi ME. High mobility group box 1 protein, a cue for stem cell recruitment. Biochem Pharmacol 2004; 68(6):1165–70.PubMedGoogle Scholar
  44. 44.
    Ley K, Laudanna C, Cybulsky MI et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7(9):678–89.PubMedGoogle Scholar
  45. 45.
    Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 2005; 6(12):1182–90.PubMedGoogle Scholar
  46. 46.
    Ruster B, Gottig S, Ludwig RJ et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006; 108(12):3938–44.PubMedGoogle Scholar
  47. 47.
    Krampera M, Pizzolo G, Aprili G et al. Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. Bone 2006; 39(4):678–83.PubMedGoogle Scholar
  48. 48.
    Minguell JJ, Erices A, Conget P. Mesenchymal stem cells. Exp Biol Med (Maywood) 2001; 226(6):507–20.Google Scholar
  49. 49.
    Sackstein R, Merzaban JS, Cain DW et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008; 14(2):181–7.PubMedGoogle Scholar
  50. 50.
    Timmermans F, Van Hauwermeiren F, De Smedt M et al. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol 2007; 27(7):1572–9.PubMedGoogle Scholar
  51. 51.
    Gallagher KA, Liu ZJ, Xiao M et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 2007; 117(5):1249–59.PubMedGoogle Scholar
  52. 52.
    Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 2007; 28(7):299–307.PubMedGoogle Scholar
  53. 53.
    Ceradini DJ, Kulkarni AR, Callaghan MJ et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10(8):858–64.PubMedGoogle Scholar
  54. 54.
    Abbott JD, Huang Y, Liu D et al. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 2004; 110(21):3300–5.PubMedGoogle Scholar
  55. 55.
    Walter DH, Haendeler J, Reinhold J et al. Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease. Circ Res 2005; 97(11):1142–51.PubMedGoogle Scholar
  56. 56.
    Hristov M, Weber C. Ambivalence of progenitor cells in vascular repair and plaque stability. Curr Opin Lipidol 2008; 19(5):491–7.PubMedGoogle Scholar
  57. 57.
    Hristov M, Zernecke A, Bidzhekov K et al. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res 2007; 100(4):590–7.PubMedGoogle Scholar
  58. 58.
    Hristov M, Zernecke A, Liehn EA et al. Regulation of endothelial progenitor cell homing after arterial injury. Thromb Haemost 2007; 98(2):274–7.PubMedGoogle Scholar
  59. 59.
    George J, Afek A, Abashidze A et al. Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2005; 25(12):2636–41.PubMedGoogle Scholar
  60. 60.
    Broxmeyer HE, Orschell CM, Clapp DW et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201(8):1307–18.PubMedGoogle Scholar
  61. 61.
    Lapidot T, Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 2002; 16(10):1992–2003.PubMedGoogle Scholar
  62. 62.
    Ceradini DJ, Gurtner GC. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc Med 2005; 15(2):57–63.PubMedGoogle Scholar
  63. 63.
    Aicher A, Heeschen C, Mildner-Rihm C et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003; 9(11):1370–6.PubMedGoogle Scholar
  64. 64.
    Schulz C, von Andrian UH, Massberg S. Hematopoietic stem and progenitor cells: their mobilization and homing to bone marrow and peripheral tissue. Immunol Res 2009; 44(1–3):160–8.PubMedGoogle Scholar
  65. 65.
    Heissig B, Hattori K, Dias S et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109(5):625–37.PubMedGoogle Scholar
  66. 66.
    Kollet O, Dar A, Shivtiel S et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 2006; 12(6):657–64.PubMedGoogle Scholar
  67. 67.
    Christopherson KW, 2nd, Cooper S, Broxmeyer HE. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood 2003; 101(12):4680–6.PubMedGoogle Scholar
  68. 68.
    Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76(2):301–14.PubMedGoogle Scholar
  69. 69.
    Potocnik AJ, Brakebusch C, Fassler R. Fetal and adult hematopoietic stem cells require beta1 integrin function for colonizing fetal liver, spleen and bone marrow. Immunity 2000; 12(6):653–63.PubMedGoogle Scholar
  70. 70.
    Levesque JP, Takamatsu Y, Nilsson SK et al. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001; 98(5):1289–97.PubMedGoogle Scholar
  71. 71.
    Papayannopoulou T, Craddock C, Nakamoto B et al. The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci USA 1995; 92(21):9647–51.PubMedGoogle Scholar
  72. 72.
    Papayannopoulou T, Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci USA 1993; 90(20):9374–8.PubMedGoogle Scholar
  73. 73.
    Wagers AJ, Allsopp RC, Weissman IL. Changes in integrin expression are associated with altered homing properties of Lin(-/lo)Thy1.1(lo)Sca-1(+)c-kit(+) hematopoietic stem cells following mobilization by cyclophosphamide/granulocyte colony-stimulating factor. Exp Hematol 2002; 30(2):176–85.PubMedGoogle Scholar
  74. 74.
    Katayama Y, Hidalgo A, Furie BC et al. PSGL-1 participates in E-selectin-mediated progenitor homing to bone marrow: evidence for cooperation between E-selectin ligands and alpha4 integrin. Blood 2003; 102(6):2060–7.PubMedGoogle Scholar
  75. 75.
    Mazo IB, Gutierrez-Ramos JC, Frenette PS et al von Andrian UH. Hematopoietic progenitor cell rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1. J Exp Med 1998; 188(3):465–74.PubMedGoogle Scholar
  76. 76.
    Hla T, Venkataraman K, Michaud J. The vascular S1P gradient-cellular sources and biological significance. Biochim Biophys Acta 2008; 1781(9):477–82.PubMedGoogle Scholar
  77. 77.
    Yatomi Y, Igarashi Y, Yang L et al. Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J Biochem 1997; 121(5):969–73.PubMedGoogle Scholar
  78. 78.
    Pappu R, Schwab SR, Cornelissen I et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007; 316(5822):295–8.PubMedGoogle Scholar
  79. 79.
    Rosen H, Gonzalez-Cabrera P, Marsolais D et al. Modulating tone: the overture of S1P receptor immunotherapeutics. Immunol Rev 2008; 223:221–35.PubMedGoogle Scholar
  80. 80.
    Massberg S, Schaerli P, Knezevic-Maramica I et al. Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph and peripheral tissues. Cell 2007; 131(5):994–1008.PubMedGoogle Scholar
  81. 81.
    Hoshino K, Takeuchi O, Kawai T et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162(7):3749–52.PubMedGoogle Scholar
  82. 82.
    Nagai Y, Garrett KP, Ohta S et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 2006; 24(6):801–12.PubMedGoogle Scholar
  83. 83.
    Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4(7):540–50.PubMedGoogle Scholar
  84. 84.
    Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107(5):1761–7.PubMedGoogle Scholar
  85. 85.
    Kaplan RN, Riba RD, Zacharoulis S et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 2005; 438(7069):820–7.PubMedGoogle Scholar
  86. 86.
    Kalka C, Masuda H, Takahashi T et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 2000; 97(7):3422–7.PubMedGoogle Scholar
  87. 87.
    Majka SM, Jackson KA, Kienstra KA et al. Distinct progenitor populations in skeletal muscle are bone marrow derived and exhibit different cell fates during vascular regeneration. J Clin Invest 2003; 111(1):71–9.PubMedGoogle Scholar
  88. 88.
    Takahashi T, Kalka C, Masuda H et al. Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5(4):434–8.PubMedGoogle Scholar
  89. 89.
    Kocher AA, Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7(4):430–6.PubMedGoogle Scholar
  90. 90.
    Orlic D, Kajstura J, Chimenti S et al. Transplanted adult bone marrow cells repair myocardial infarcts in mice. Ann N Y Acad Sci 2001; 938:221–9; discussion 29–30.PubMedGoogle Scholar
  91. 91.
    Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410(6829):701–5.PubMedGoogle Scholar
  92. 92.
    Kaushal S, Amiel GE, Guleserian KJ et al. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat Med 2001; 7(9):1035–40.PubMedGoogle Scholar
  93. 93.
    Shi Q, Rafii S, Wu MH et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998; 92(2):362–7.PubMedGoogle Scholar
  94. 94.
    Sata M, Saiura A, Kunisato A et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8(4):403–9.PubMedGoogle Scholar
  95. 95.
    Grant MB, May WS, Caballero S et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med 2002; 8(6):607–12.PubMedGoogle Scholar
  96. 96.
    Otani A, Kinder K, Ewalt K et al. Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med 2002; 8(9):1004–10.PubMedGoogle Scholar
  97. 97.
    Young PP, Hofling AA, Sands MS. VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients. Proc Natl Acad Sci USA 2002; 99(18):11951–6.PubMedGoogle Scholar
  98. 98.
    Lyden D, Hattori K, Dias S et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7(11):1194–201.PubMedGoogle Scholar
  99. 99.
    Reyes M, Dudek A, Jahagirdar B et al. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002; 109(3):337–46.PubMedGoogle Scholar
  100. 100.
    Peled A, Petit I, Kollet O et al. Dependence of human stem cell engraftment and repopulation of NOD/ SCID mice on CXCR4. Science 1999; 283(5403):845–8.PubMedGoogle Scholar
  101. 101.
    Sugiyama T, Kohara H, Noda M et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006; 25(6):977–88.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2010

Authors and Affiliations

  • Ying Zhuge
    • 1
    • 3
  • Zhao-Jun Liu
    • 1
    • 2
  • Omaida C. Velazquez
    • 1
    • 2
  1. 1.DeWitt Daughtry Family Department of SurgeryDivision of Vascular SurgeryMiamiUSA
  2. 2.Sylvester Comprehensive Cancer Center Miller School of MedicineUniversity of MiamiMiamiUSA
  3. 3.Miller School of MedicineUniversity of MiamiMiamiUSA

Personalised recommendations